Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.
The anti-oestrogen tamoxifen, which is widely used as adjuvant therapy for breast cancer, is undergoing evaluation as a chemopreventive agent in women at increased risk of developing this disease. Recent results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 prevention trial show a 49% reduction in breast cancer incidence in healthy, high-risk women. However, tamoxifen treatment has the serious side effect of increasing the incidence of endometrial cancer in women and long-term administration of tamoxifen causes hepatic tumours in rats. These liver tumours are induced via a genotoxic mechanism, but the mechanisms responsible for endometrial cancer in women are not yet known and are a focus of much debate. This review describes the findings from the chemoprevention trials and problems associated with the use of tamoxifen in this setting. The mechanism of carcinogenesis in rat liver is explained in detail and compared to the situation in humans, with a view to assessing the risks associated with tamoxifen therapy and predicting whether other anti-oestrogens might be safer alternatives.
Brown
Karen
K
Cancer Biomarkers and Prevention Group, The Biocentre, University of Leicester, University Road, Leicester, LE1 7RH, UK. kb20@le.ac.uk
D000818:Animals; D001943:Breast Neoplasms / Q000517:prevention & control*; D018736:DNA Adducts / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D051381:Rats; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use
D018736:DNA Adducts; D004965:Estrogen Antagonists; D013629:Tamoxifen